Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus …

9 hours ago · Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has earned a consensus rating of "Buy" from the fourteen research firms that are covering the company, …

$180.00
OFF

Axsome Shares Boosted By Strong Phase 3 Outcomes And Buy …

2 weeks from now

Dec 31, 2024 · On Tuesday, H.C. Wainwright reaffirmed its Buy rating on Axsome Therapeutics (NASDAQ: AXSM) shares, maintaining a price target of $180.00.Currently trading at $84.78, …

investing.com

$180.00
OFF

Axsome Shares Reiterate Buy Rating On Strong Q3 Results

2 weeks from now

Nov 25, 2024 · On Monday, H.C. Wainwright maintained a Buy rating and a $180.00 stock price target on Axsome Therapeutics (NASDAQ: AXSM), highlighting the company's strong financial …

investing.com

$125.00
OFF

TD Cowen Keeps Their Buy Rating On Axsome Therapeutics (AXSM)

2 weeks from now

Dec 30, 2024 · TD Cowen analyst Joseph Thome maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $125.00. The …

businessinsider.com

$84.61
OFF

Axsome Therapeutics (NASDAQ:AXSM) Given “Buy” Rating At HC …

2 weeks from now

Jan 1, 2025 · NASDAQ:AXSM opened at $84.61 on Tuesday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. Axsome Therapeutics has a fifty …

defenseworld.net

$180
OFF

Truist Raises Axsome Stock Target To $180, Maintains Buy Rating

2 weeks from now

5 days ago · On Friday, Truist Securities updated its outlook on Axsome Therapeutics (NASDAQ: AXSM), increasing the price target on the company's stock to $180 from the previous target of …

investing.com

$84.78
OFF

Axsome Therapeutics (NASDAQ:AXSM) Given Buy Rating At …

2 weeks from now

Dec 31, 2024 · NASDAQ:AXSM opened at $84.78 on Monday. The company has a market cap of $4.11 billion, a P/E ratio of -12.98 and a beta of 1.18. Axsome Therapeutics has a twelve …

defenseworld.net

$130.00
OFF

Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 …

2 weeks from now

Dec 30, 2024 · 8 analysts have expressed a variety of opinions on Axsome Therapeutics (NASDAQ:AXSM) ... Buy: $130.00: $130.00: ... Stay up to date on Axsome Therapeutics …

nasdaq.com

3%
OFF

Axsome Therapeutics (NASDAQ:AXSM) Shares Up 5.3% Following …

2 weeks from now

3 hours ago · Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report)’s stock price traded up 5.3% during trading on Monday after Truist Financial raised their price target on the …

etfdailynews.com

$150
OFF

Truist Says ‘aggressive’ Buying Axsome Therapeutics After

2 weeks from now

Dec 31, 2024 · Truist analyst Joon Lee keeps a Buy rating and $150 price target on Axsome Therapeutics (AXSM) while noting that the firm is an "aggressive buyer" of the stock after the …

nasdaq.com

87%
OFF

Axsome Therapeutics' (AXSM) "Buy" Rating Reaffirmed At …

2 weeks from now

1 day ago · Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter last year, the company posted ($1.32) EPS. …

marketbeat.com

$130.00
OFF

Axsome Therapeutics (NASDAQ:AXSM) Given Buy Rating At

2 weeks from now

Dec 30, 2024 · Royal Bank of Canada boosted their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an "outperform" rating in a research note on Friday, …

marketbeat.com

$180
OFF

Truist Alza Il Target Di Axsome Therapeutics A $180, Mantiene Buy

2 weeks from now

2 days ago · Lunedì, Truist Securities ha modificato le sue previsioni su Axsome Therapeutics (NASDAQ:AXSM), aumentando il target di prezzo a $180 dal precedente $150, mantenendo …

investing.com

$180
OFF

Truist Raises Axsome Therapeutics Target To $180, Maintains Buy

2 weeks from now

2 days ago · On Monday, Truist Securities adjusted its outlook on Axsome Therapeutics (NASDAQ: AXSM), increasing the price target to $180 from the previous $150, while …

investing.com

FAQs about Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus … Coupon?

Should you buy Axsome Therapeutics (axsm – research report)?

TD Cowen analyst Joseph Thome maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $125.00. The company’s shares opened today at $82.00. According to TipRanks, Thome is an analyst with an average return of -1.0% and a 42.94% success rate. ...

Should you buy axis Therapeutics (Axsome) stock?

Axsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings. Axsome Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. ...

Where can I buy Axsome Therapeutics stock?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Axsome Therapeutics own? ...

Who owns Axsome Therapeutics?

Mirae Asset Global Investments Co. Ltd. boosted its holdings in Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares during the period. ...

How much did Axsome Therapeutics (axsm) raise?

Axsome Therapeutics (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. ...

Who is Axsome Therapeutics (axsm)?

Begin your TipRanks Premium journey today. Axsome Therapeutics (AXSM) Company Description: Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. ...